These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1585 related items for PubMed ID: 25420924

  • 1. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

  • 2. Urocortin-2 improves right ventricular function and attenuates pulmonary arterial hypertension.
    Adão R, Mendes-Ferreira P, Santos-Ribeiro D, Maia-Rocha C, Pimentel LD, Monteiro-Pinto C, Mulvaney EP, Reid HM, Kinsella BT, Potus F, Breuils-Bonnet S, Rademaker MT, Provencher S, Bonnet S, Leite-Moreira AF, Brás-Silva C.
    Cardiovasc Res; 2018 Jul 01; 114(8):1165-1177. PubMed ID: 29584808
    [Abstract] [Full Text] [Related]

  • 3. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X, Chen C, Dong W.
    J Vasc Surg; 2016 Nov 01; 64(5):1468-1477. PubMed ID: 26527422
    [Abstract] [Full Text] [Related]

  • 4. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A, Trappiel M, Berghausen EM, Ten Freyhaus H, Wellnhofer E, Odenthal M, Blaschke F, Er F, Gassanov N, Rosenkranz S, Baldus S, Kappert K, Caglayan E.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr 01; 389(4):369-79. PubMed ID: 26742933
    [Abstract] [Full Text] [Related]

  • 5. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension.
    Nogueira-Ferreira R, Ferreira-Pinto MJ, Silva AF, Vitorino R, Justino J, Costa R, Moreira-Gonçalves D, Quignard JF, Ducret T, Savineau JP, Leite-Moreira AF, Ferreira R, Henriques-Coelho T.
    J Cell Physiol; 2017 Nov 01; 232(11):3128-3138. PubMed ID: 28036116
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ranolazine prevents INaL enhancement and blunts myocardial remodelling in a model of pulmonary hypertension.
    Rocchetti M, Sala L, Rizzetto R, Staszewsky LI, Alemanni M, Zambelli V, Russo I, Barile L, Cornaghi L, Altomare C, Ronchi C, Mostacciuolo G, Lucchetti J, Gobbi M, Latini R, Zaza A.
    Cardiovasc Res; 2014 Oct 01; 104(1):37-48. PubMed ID: 25139747
    [Abstract] [Full Text] [Related]

  • 8. 2-Methoxyestradiol mediates the protective effects of estradiol in monocrotaline-induced pulmonary hypertension.
    Tofovic SP, Zhang X, Jackson EK, Dacic S, Petrusevska G.
    Vascul Pharmacol; 2006 Dec 01; 45(6):358-67. PubMed ID: 16872912
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Sulforaphane Improves Redox Homeostasis and Right Ventricular Contractility in a Model of Pulmonary Hypertension.
    Conzatti A, Colombo R, Siqueira R, Campos-Carraro C, Turck P, Luz de Castro A, Belló-Klein A, Sander da Rosa Araujo A.
    J Cardiovasc Pharmacol; 2024 Jun 01; 83(6):612-620. PubMed ID: 38547510
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.
    Nan X, Su S, Ma K, Ma X, Wang X, Zhaxi D, Ge R, Li Z, Lu D.
    J Ethnopharmacol; 2018 Apr 24; 216():175-183. PubMed ID: 29325918
    [Abstract] [Full Text] [Related]

  • 17. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
    Leong ZP, Hikasa Y.
    Vascul Pharmacol; 2018 Nov 24; 110():31-41. PubMed ID: 30071297
    [Abstract] [Full Text] [Related]

  • 18. Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure?
    Balestra GM, Mik EG, Eerbeek O, Specht PA, van der Laarse WJ, Zuurbier CJ.
    Respir Res; 2015 Feb 03; 16(1):6. PubMed ID: 25645252
    [Abstract] [Full Text] [Related]

  • 19. Progesterone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension in estrogen-deficient rats.
    Tofovic PS, Zhang X, Petrusevska G.
    Prilozi; 2009 Jul 03; 30(1):25-44. PubMed ID: 19736529
    [Abstract] [Full Text] [Related]

  • 20. Neutralization of CXCL12 attenuates established pulmonary hypertension in rats.
    Bordenave J, Thuillet R, Tu L, Phan C, Cumont A, Marsol C, Huertas A, Savale L, Hibert M, Galzi JL, Bonnet D, Humbert M, Frossard N, Guignabert C.
    Cardiovasc Res; 2020 Mar 01; 116(3):686-697. PubMed ID: 31173066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 80.